# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **AIMOVIG®** (erenumab-aooe) | Neuroscience | Pediatric Migraine | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients.<br><br>**ADDITIONAL INFORMATION**<br>Aimovig is developed in partnership with Novartis. | | | |
| **AMJEVITA®** (adalimumab-atto) | Inflammation | Interchangeability | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>AMJEVITA (adalimumab-atto) is a biosimilar to HUMIRA® (adalimumab), which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha.<br><br>**ADDITIONAL INFORMATION**<br>HUMIRA is a registered trademark of AbbVie Biotechnology Ltd.<br>AMJEVITA is a trademark of Amgen Inc. | | | |
| **BEMARITUZUMAB** | Hematology/Oncology | Gastric and Gastroesophageal Junction (GEJ) Cancers | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric and Gastroesophageal Junction (GEJ) Cancers.<br><br>**ADDITIONAL INFORMATION**<br>In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for bemarituzumab.<br><br>**ADDITIONAL CLINICAL STUDIES**<br>Bemarituzumab is also in Phase 1 and Phase 2 development for the treatment of advanced Gastric and Gastroesophageal cancers in combination with other therapies. | | | |
| | Hematology/Oncology | Other Tumors | Monoclonal Antibody | 2 |
| | **DESCRIPTION**<br>Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced solid tumors other than advanced squamous non-small cell lung cancer. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **BLINCYTO®** (blinatumomab) | Hematology/Oncology | Acute Lymphoblastic Leukemia | BiTE® Molecule | 3 |
| | **DESCRIPTION**<br>BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in newly diagnosed adults age 40 and older with Ph negative B-Cell precursor Acute Lymphoblastic Leukemia (ALL).<br><br>**ADDITIONAL INFORMATION**<br>In October 2023, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation to BLINCYTO.<br><br>**ADDITIONAL CLINICAL STUDIES**<br>BLINCYTO is also in Phase 1 development being investigated for subcutaneous administration for the treatment of adults with relapsed/refractory Acute Lymphoblastic Leukemia (ALL). | | | |
| **DAZODALIBEP** | Rare Disease | Sjögren's Disease | Fusion Protein | 3 |
| | **DESCRIPTION**<br>Dazodalibep is a fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. It is being investigated for the treatment of Sjögren's disease. | | | |
| **EVENITY®** (romosozumab-aqqg) | Bone | Male Osteoporosis | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis.<br><br>**ADDITIONAL INFORMATION**<br>EVENITY is being developed in collaboration with UCB. | | | |
| | Bone | Pediatric Osteogenesis Imperfecta | Monoclonal Antibody | 1 |
| | **DESCRIPTION**<br>EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients.<br><br>**ADDITIONAL INFORMATION**<br>EVENITY is being developed in collaboration with UCB. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **KYPROLIS®** (carfilzomib) | Hematology/Oncology | Multiple Myeloma | Small Molecule | 3 |
| | **DESCRIPTION**<br>KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma. | | | |
| | Hematology/Oncology | Pediatric Acute Lymphoblastic Leukemia | Small Molecule | 2 |
| | **DESCRIPTION**<br>KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients. | | | |
| **LUMAKRAS®** (sotorasib) | Hematology/Oncology | Advanced Colorectal Cancer | Small Molecule | 3 |
| | **DESCRIPTION**<br>LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of advanced colorectal cancer.<br><br>**ADDITIONAL INFORMATION**<br>LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC in combination with other therapies.<br><br>In August 2023, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation to LUMAKRAS. | | | |
| | Hematology/Oncology | Non-Small Cell Lung Cancer | Small Molecule | 3 |
| | **DESCRIPTION**<br>LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.<br><br>**ADDITIONAL INFORMATION**<br>LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing authorization has subsequently been granted in the European Union as well as in additional countries, including some under FDA's Project Orbis initiative, such as Canada and U.K. Additional marketing applications are also under review.<br><br>**ADDITIONAL CLINICAL STUDIES**<br>LUMAKRAS is also in Phase 1 and Phase 2 development for the treatment of NSCLC in combination with other therapies. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **LUMAKRAS®** (sotorasib) | Hematology/Oncology | Other Tumors | Small Molecule | 2 |
| | **DESCRIPTION**<br>LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer.<br><br>**ADDITIONAL INFORMATION**<br>LUMAKRAS is being investigated in previously treated KRAS G12C-mutated solid tumors in combination with other therapies. | | | |
| **NPLATE®** (romiplostim) | Hematology/Oncology | Chemotherapy-Induced Thrombocytopenia | Peptibody | 3 |
| | **DESCRIPTION**<br>Nplate is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT). | | | |
| **OLPASIRAN** (formerly AMG 890) | Cardiometabolic | Cardiovascular Disease | siRNA | 3 |
| | **DESCRIPTION**<br>Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease. | | | |
| **OTEZLA®** (apremilast) | Inflammation | Pediatric Plaque Psoriasis | Small Molecule | 3 |
| | **DESCRIPTION**<br>Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe plaque psoriasis in pediatric patients. | | | |
| | Inflammation | Juvenile Psoriatic Arthritis | Small Molecule | 3 |
| | **DESCRIPTION**<br>Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN 

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **OTEZLA®** (apremilast) | Inflammation | Pediatric Behcet's Disease | Small Molecule | 3 |
| | **DESCRIPTION** Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet's disease in pediatric patients. | | | |
| | Inflammation | Palmoplantar Pustulosis | Small Molecule | 3 |
| | **DESCRIPTION** Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of palmoplantar pustulosis. | | | |
| **PARSABIV®** (etelcalcetide) | Nephrology | Pediatric Secondary Hyperparathyroidism | Peptide | 3 |
| | **DESCRIPTION** Parsabiv is a calcium-sensing receptor agonist. It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis. | | | |
| **PROLIA®** (denosumab) | Bone | Pediatric Glucocorticoid-Induced Osteoporosis | Monoclonal Antibody | 3 |
| | **DESCRIPTION** Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients. | | | |
| **REPATHA®** (evolocumab) | Cardiometabolic | Hypercholesterolemia | Monoclonal Antibody | 3 |
| | **DESCRIPTION** Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in patients at high cardiovascular risk without a prior myocardial infarction or stroke. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **ROCATINLIMAB**<br>**(formerly AMG 451 / KHK4083)** | Inflammation | Atopic Dermatitis | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>Rocatinlimab (formerly AMG 451 / KHK4083) is an anti-OX40 monoclonal antibody that inhibits activated OX40 expressing T cells and reduces their number. It is being investigated for the treatment of moderate-to-severe atopic dermatitis.<br><br>**ADDITIONAL INFORMATION**<br>AMG 451 (KHK4083) is being developed in collaboration with Kyowa Kirin Co., Ltd. | | | |
| **TARLATAMAB**<br>**(formerly AMG 757)** | Hematology/Oncology | Small Cell Lung Cancer | BiTE® Molecule | 3 |
| | **DESCRIPTION**<br>Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small cell lung cancer.<br><br>**ADDITIONAL INFORMATION**<br>In October 2023, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for tarlatamab.<br><br>**ADDITIONAL CLINICAL STUDIES**<br>Tarlatamab is also in Phase 1 in combination with other therapies. | | | |
| | Hematology/Oncology | Neuroendocrine Prostate Cancer | BiTE® Molecule | 1 |
| | **DESCRIPTION**<br>Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer. | | | |
| **TEZSPIRE®**<br>**(tezepelumab-ekko)** | Inflammation | Severe Asthma | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>TEZSPIRE is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the reduction of oral corticosteroid use in adults with oral corticosteroid dependent asthma.<br><br>**ADDITIONAL INFORMATION**<br>TEZSPIRE is being developed in collaboration with AstraZeneca plc. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **TEZSPIRE®** (tezepelumab-ekko) | Inflammation | Chronic Rhinosinusitis with Nasal Polyps | Monoclonal Antibody | 3 |
| | **DESCRIPTION** TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc. | | | |
| | Inflammation | Eosinophilic Esophagitis | Monoclonal Antibody | 3 |
| | **DESCRIPTION** TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of eosinophilic esophagitis (EoE). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc. | | | |
| | Inflammation | Chronic Obstructive Pulmonary Disease | Monoclonal Antibody | 2 |
| | **DESCRIPTION** TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc. | | | |
| | Inflammation | Chronic Spontaneous Urticaria | Monoclonal Antibody | 2 |
| | **DESCRIPTION** TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic spontaneous urticaria (CSU). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc. | | | |
| **UPLIZNA®** *(inebilizumab-cdon)* | Rare Disease | IgG4-Related Disease | Monoclonal Antibody | 3 |
| | **DESCRIPTION** Uplizna is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated for the prevention of flares in patients with IgG4-related disease. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **UPLIZNA®** *(inebilizumab-cdon)* | Rare Disease | Myasthenia Gravis | Monoclonal Antibody | 3 |
| | **DESCRIPTION** Uplizna is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated for improving outcomes in patients with myasthenia gravis. | | | |
| **WEZLANA™** (formerly ABP 654) (ustekinumab) | Inflammation | Investigational Biosimilar | Monoclonal Antibody | 3 |
| | **DESCRIPTION** WEZLANA™ (formerly ABP 654) is an investigational biosimilar to STELARA (ustekinumab), which is a monoclonal antibody that inhibits IL-12 and IL-23. **ADDITIONAL INFORMATION** STELARA is a registered trademark of Johnson & Johnson. | | | |
| **ABP 206** (Investigational biosimilar to OPDIVO® (nivolumab)) | Hematology/Oncology | Investigational Biosimilar | Monoclonal Antibody | 3 |
| | **DESCRIPTION** ABP 206 is an investigational biosimilar to OPDIVO (nivolumab), which is a monoclonal antibody that binds to the receptor protein called programmed death protein 1 (PD-1). **ADDITIONAL INFORMATION** OPDIVO is a registered trademark of Bristol-Myers Squibb Company. | | | |
| **ABP 938** (Investigational biosimilar to EYLEA® (aflibercept)) | Inflammation | Investigational Biosimilar | Fusion Protein | 3 |
| | **DESCRIPTION** ABP 938 is an investigational biosimilar to EYLEA (aflibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein. **ADDITIONAL INFORMATION** EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **ABP 959**<br>**(Investigational biosimilar to SOLIRIS® (eculizumab))** | Hematology/Oncology | Investigational Biosimilar | Monoclonal Antibody | 3 |
| | **DESCRIPTION**<br>ABP 959 is an investigational biosimilar to SOLIRIS (eculizumab), which is a monoclonal antibody that specifically binds to the complement protein C5.<br><br>**ADDITIONAL INFORMATION**<br>SOLIRIS is a registered trademark of Alexion Pharmaceuticals, Inc. | | | |
| **DAXDILIMAB** | Rare Disease | Dermatomyositis and Anti-Synthetase Inflammatory Myositis | Monoclonal Antibody | 2 |
| | **DESCRIPTION**<br>Daxdilimab is a fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. It is being investigated for the treatment of dermatomyositis and anti-synthetase inflammatory myositis. | | | |
| | Rare Disease | Discoid Lupus Erythematosus | Monoclonal Antibody | 2 |
| | **DESCRIPTION**<br>Daxdilimab is a fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. It is being investigated for the treatment of discoid lupus erythematosus. | | | |
| **EFAVALEUKIN ALFA**<br>**(formerly AMG 592)** | Inflammation | Ulcerative Colitis | Fusion Protein | 2 |
| | **DESCRIPTION**<br>Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of ulcerative colitis. | | | |
| **FIPAXALPARANT** | Rare Disease | Diffuse Cutaneous Systemic Sclerosis | Small Molecule | 2 |
| | **DESCRIPTION**<br>Fipaxalparant is a molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). It is being investigated for the treatment of diffuse cutaneous systemic sclerosis. | | | |
| | Rare Disease | Idiopathic Pulmonary Fibrosis | Small Molecule | 2 |
| | **DESCRIPTION**<br>Fipaxalparant is a molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). It is being investigated for the treatment of idiopathic pulmonary fibrosis. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **MARIDEBART CAFRAGLUTIDE** (MariTide, formerly AMG 133) | Cardiometabolic | Obesity | Antibody-Peptide Conjugate | 2 |
| | **DESCRIPTION** Maridebart cafraglutide (MariTide, formerly AMG 133) is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity. | | | |
| **ORDESEKIMAB**** (formerly AMG 714 / PRV-015) | Inflammation | Celiac Disease | Monoclonal Antibody | 2 |
| | **DESCRIPTION** Ordesekimab (formerly AMG 714/PRV-015) is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of non-responsive celiac disease as an adjunct to a gluten free diet.<br><br>**ADDITIONAL INFORMATION** Ordesekimab is being developed in collaboration with Provention Bio, a Sanofi company. | | | |
| **TEPEZZA®** (*teprotumumab-trbw*) | Rare Disease | Thyroid Eye Disease | Monoclonal Antibody | 1 |
| | **DESCRIPTION** Tepezza is a monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R). It is being investigated for subcutaneous administration for the treatment of moderate-to-severe active thyroid eye disease. | | | |
| **XALURITAMIG** (formerly AMG 509) | Hematology/Oncology | Prostate Cancer | XmAb® Antibody | 1 |
| | **DESCRIPTION** AMG 509 (STEAP1 XmAb antibody) is a bivalent T cell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer.<br><br>**ADDITIONAL INFORMATION** XmAb is a registered trademark of Xencor, Inc. | | | |
| **AMG 104** | Inflammation | Asthma | Monoclonal Antibody | 1 |
| | **DESCRIPTION** AMG 104 is a human anti-TSLP Fab. It is being investigated for the treatment of asthma.<br><br>**ADDITIONAL INFORMATION** AMG 104 is being developed in collaboration with AstraZeneca plc. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

# AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **AMG 176** | Hematology/Oncology | Hematology | Small Molecule | 1 |
| | **DESCRIPTION**<br>AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies. | | | |
| **AMG 193** | Hematology/Oncology | Solid Tumors | Small Molecule | 1 |
| | **DESCRIPTION**<br>AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors.<br><br>**ADDITIONAL CLINICAL STUDIES**<br>AMG 193 is also in Phase 1 development for treatment of solid tumors in combination with other therapy. | | | |
| **AMG 305** | Hematology/Oncology | Colorectal Cancer | BiTE® Molecule | 1 |
| | **DESCRIPTION**<br>AMG 305 is a dual-targeting bispecific T cell engager (BiTE) molecule against P-cadherin (CDH3), mesothelin (MSLN) and CD3. It is being investigated for the treatment of solid tumors. | | | |
| **AMG 329**<br>**(formerly HZN-1116)** | Rare Disease | Autoimmune Diseases | Monoclonal Antibody | 1 |
| | **DESCRIPTION**<br>AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. It is being investigated for the treatment of autoimmune diseases. | | | |
| **AMG 355** | Hematology/Oncology | Solid Tumors | Monoclonal Antibody | 1 |
| | **DESCRIPTION**<br>AMG 355 is an anti-CCR8 monoclonal antibody. It is being investigated for the treatment of advanced solid tumor malignancies. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.


| MOLECULE NAME | THERAPEUTIC AREA | INVESTIGATIONAL INDICATION | MODALITY | PHASE |
|---|---|---|---|---|
| **AMG 651** | Hematology/Oncology | Colorectal Cancer | Bispecific T-Cell Engager | 1 |
| | **DESCRIPTION**<br>AMG 651 (CX-904) is a T-cell engaging bispecific Probody® candidate against epidermal growth factor receptor (EGFR) and CD3. It is being investigated for the treatment of solid tumors.<br><br>**ADDITIONAL INFORMATION**<br>AMG 651 is being developed in collaboration with CytomX Therapeutics, Inc. | | | |
| **AMG 786** | Cardiometabolic | Obesity | Small Molecule | 1 |
| | **DESCRIPTION**<br>AMG 786 is a small molecule being investigated for the treatment of obesity. | | | |
| **AMG 794** | Hematology/Oncology | Solid Tumors | BiTE® Molecule | 1 |
| | **DESCRIPTION**<br>AMG 794 is a half-life extended (HLE) anti-claudin 6 (CLDN6) bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of solid tumors. | | | |

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 6, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.